Thank you.
I'd like to come back to the question that my colleague Mr. Dhaliwal raised about aggregated prescribing information and the possible necessity for a carve-out and a clearly defined exemption.
Due to medical advances we have an increasing number of drug therapies to treat all kinds of health conditions. We have medical practitioners who require scientific information about the impact of certain prescribing profiles. We have researchers who also require this kind of information.
Do you not think it is possible to do a very clear carve-out that would provide an exemption for aggregated prescribing information that would not affect the fears you have of weakening privacy protection for personal information if a definition of “work product ” is done, because that would make it so large as to weaken that protection? Is that something you think could be considered?